FibromEd and Sistemic are engaged in a collaborative project to identify important microRNA (miRNA) signatures, required for high fidelity human hepatocyte generation from pluripotent stem cells. The project is funded by the Scottish Stem Cell Network.
Sistemic is delighted to announce that its proprietary technology (SistemQC™) has been chosen to form a key part of the research and production process for a landmark multinational collaborative project led by TiGenix, Belgium and including partners from Spain, France, the Netherlands as well as the UK and Belgium.
Sistemic, the stem cell and drug development technology company, has won a substantial Scottish Regional Selective Assistance (RSA) grant from Scottish Enterprise. The grant forms part of a £1M planned investment programme which, on the back of a very successful year for the company, will see Sistemic more than double the size of its operations.
Glasgow, Scotland Sistemic Ltd announced today the award of an Innovate UK grant to further develop, to a market-ready stage, its groundbreaking prototype microRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products.
Sistemic Ltd. announced today the publication of its ground-breaking research, undertaken together with TiGenix, identifying a set of circulating miRNA biomarkers which could potentially be used, if further clinically validated, to stratify refractory rheumatoid arthritis patients, prior to treatment, into responders and non-responders to an allogenic cell-based therapy:
Glasgow, Scotland. Sistemic Ltd. announced today that it has recently published, in collaboration with colleagues at Institute of Infection, Inflammation and Immunity, Glasgow Biomedical Research Centre, University of Glasgow, evidence of significant and potentially functionally relevant differences between MSCs from Olfactory Mucosa and from Bone Marrow revealed by miRNA profiling.
Glasgow, Scotland. Sistemic Ltd. today announced the launch of its first predictive diagnostic product for protein production utilising its novel miRNA technologies including SistemQC™, SistemSeek™ and SistemExpress™. The introduction of the first product in the new SistemCheck™ range will be for the prediction of indoleamine 2,3-dioxygenase (IDO) production in cells.